Multiple Myeloma is a cancer of the antibody producing plasma cells in the body. Unfortunately, at the moment Multiple Myeloma is incurable. While the patient initially responds to treatment the cancer eventually relapses and regrows. Our research group Targeted Therapeutics in Cancer composed of molecular biologists and medicinal chemists is located in the Department of Physiology and Medical Physics (https://www.rcsi.com/people/profile/tnichonghaile). We are interested in identifying novel therapeutics for chemoresistant cancer. It is known that both epigenetic and metabolic modifications can drive resistance to cancer treatment. We recently described a new role for histone deacetylase 6 in regulating glycolytic metabolism in Science Advances (https://www.science.org/doi/abs/10.1126/sciadv.abc4897).
Our aim in this project is to uncover the epigenetic and metabolic landscape of relapsed/refractory primary patient multiple myeloma samples. To do this we will use state-of-the-art technologies including CUT&TAG to define epigenetic marks and metabolic profiling assays such as Seahorse and SCENITH. The goal is to understand if the metabolic state of the cells is epigenetically regulated. Excitingly, this project involves close collaboration with our clinical colleagues at Beaumont Hospital. This project is suited to a highly ambitious, driven student with a research interest in metabolism and epigenetics.
Entry requirements
Applicants must have received a first class or upper second class (2.1) honours degree or equivalent in Biochemistry/Physiology or relevant subject.
Desirable qualifications include:
- previous experience with mammalian cell culture and basic molecular biology techniques including Western Blotting and qRT-PCR.
- Excellent written and oral English.
How do I apply
To apply, please access the following link and complete the application form in full: https://forms.office.com/r/pMY8NuGdEx
- Unfortunately, we are unable to provide individual feedback to applicants.
- Shortlisted candidates will be invited for interview.
- At this stage only successful candidates will be contacted to submit, CV, transcripts and other relevant documentation.
- Only their referees will also be contacted at this stage for a reference.
Applications must include:
- a completed application form
- English language requirements – see https://www.rcsi.com/dublin/postgraduate/policies-and-guidelines/english-language-requirements.
Deadline: All applications must be made online by 31 July 2022 (GMT)
It is the candidate’s responsibility to ensure the application form is completed in full on time. Late and/or incomplete applications will not normally be assessed.
Further information on the Royal College of Surgeons in Ireland can be found here: https://www.rcsi.com/
Position start date: October 2022
Expected shortlisting date: August 7th 2022
Expected interview date: Week of August 15th-19th 2022
Continue with Facebook